Th is paper analyses the e-discourse surrounding the dream of a Dutch scientist, Dr
Introduction
On his quest to place Indonesia on the genetic world map, a Dutch scientist named Dr X 2 spread the word that he would set up the largest biomedical research centre in Indonesia, using blood samples gathered from various laboratories, medical centres, and the jungle. He would study genes for familial syndromes, such as cancers and forms of mental retardation, some of which are considered to be particular for certain ethnic groups in Indonesia.
PT Sanbe Farma, a manufacturer of pharmaceuticals in Bandung (West Java) in 2001 announced its decision to start a registry of inherited diseases of the Indonesian people in all her genetic diversity. Th e project was advertised as 'a stimulus for future Central Government initiatives for a Human Genomics program to be established in this vast country of more than 220 million people and its enormous genetic resources ' (cf. www.sanbe-farma.com/biotech. html, 8 Feb 2006) . Its leader was Dr X.
Much has been written on the targets of the Human Genome Diversity Project (HGDP) (Cavalli-Sforza & Cavalli-Sforza 1995; Reardon 2001: 365) , but the incentives for and motives of geneticists to set up human genetic biobanks are little understood. Many works on science and society have theoretically 'framed' the practices of human genetics as imperialist (Desowitz 2002; Harry 2000; Lock 1994; Macer 1997; Marshall 1997; Rifkin 1998) , racist (Gordimer 2002; Lewontin 2001: 1-40; Reardon 2004) , and positivist (Carlson & Stimeling 2002) , or hailed it as human exploration (Avise 2001; Stock 2003; Sykes 2002 ) and saviour of mankind (Savalescu 2001; Harris 1998 ). Other attempts have been made to relate human genetic biobanks to the creation of 'imagined communities' (Busby & Martin 2006) .
Th is chapter tries to understand the relationship between the motivation of a scientist to bank human genetic data and the institutional context in which the banking takes place. I intend to do this on the basis of e-mail correspondence that took place between Dr X and a group of people that he involved in his plans to set up an HGDP in Indonesia. Much of this correspondence was copied to a group of people, and one researcher invited to participate in Dr X's project pointed out to me its relevance to discussions on 'Western' views of science and its practices in 'non-Western' cultures. By analyzing Dr X's e-letters to fellow scientists, academics, and politicians, some of whom I shall refer to by using their initials only, 3 I provide six perspectives on Dr X's plans to move his work on genetics to Indonesia. Th ey are summarised as the paradigms of Progress (section 2) and Exploitation (section 3).
Views in favour of Dr X initiative to set up a registry of inherited diseases in Indonesia would look forward to a future in which scientific progress will bring financial and healthcare improvement to the needy. Such progressive views on human genetic biobanking pay attention to its scientific value, the academic and research opportunities it provides for researchers and entrepreneurs in Indonesia, the Netherlands, and elsewhere, the potential medical fruits it generates in the field of molecular diagnostics, new insights into disease (and their cures), and a boost for the institutional development of a country to optimally use its resources. Critical perspectives, as shall become clear, observe Dr X's e-correspondence from a much less favourable angle. Th eir critique includes accusations of genetic reductionism, the exploitation of cheap labour, theft of human body materials, and an Orientalist attitude.
Th e question is, however, whether these contrasting perspectives contribute to a better understanding of undesirable or unethical practices. Th is question I try to answer in the second part of the article (section 4), where I discuss the institutional embedding of the Dr X case. I claim that the validity of the theoretical perspectives used to analyse the Dr X case depends on whether they sufficiently take into account the institutional embedding. An institutional approach to human biobanking should incorporate an assessment of socioeconomic inequalities, on both an international and national level, public healthcare needs, research regulation, and differences in academic cultures from a comparative perspective. Rather than focusing on the 'right' cultural politics and ethical attitude towards biobanking, such institutional approach to biobanking, then, takes seriously: first, the organisational framework that carries the political economy of a country; second, the ways in which it is linked transnationally to regional research and commercial organisations; third, the way in which it compares internationally to other political economies; and fourth, the way in which biobanking organisations and the institutions linked to it are mediated through culture.
Th e second half of this article then explores the implications of the institutional environment for the introduction of new genetic technologies, rather than the possible consequences of the introduction of biobanking for Indonesia, and it shall make some observations on the use of the paradigms discussed.
Beginnings
Why should anyone want to know about a retired scientist hoping to fulfil a dream of scientific and human progress? Is that not what scientists always say they dream about? I propose here that in order to understand developments in science and innovation we should take those dreams seriously. Dr X, having been offered a job as director of the Biotechnology section in Sanbe Farma (est. 1975) , the largest pharmaceutical company in Indonesia, 4 decided to take the chance and move to Bandung in West Java. Sanbe Farma has hoped to use the expertise and network of Dr X to expand its pharmaceutical activities in the area of biobanking. At the same time while sharing his scientific experience and network of connections to set up a disease registry, the genetic sampling activities it required would serve a clear scientific aim.
Finishing a respectable career as a scientist and academic at the Free University of Amsterdam at sixty years of age, and having built up a publication record exceeding 300 articles published in peer-reviewed scientific journals, Dr X decided to start a new career. It would be a true new beginning. Not so much because it required his relocation in another part of the world, but rather because it meant a new challenge among people who would appreciate him and who would not put a myriad of bureaucratic guidelines and rules in the way of progressing in science. And last but not least, his new post would allow him to realise his dream of placing Indonesia on the world's human DNA map. A homepage called 'Th e Indonesian Hereditary Disease Registry' would offer to the whole world of human geneticists: the analysis of the germ line mutations involved in all kinds of diseased families, in a country with 200 different extended families or 'ethnic groups' if you wish to call them in that way. A dream to come true, or a nightmare? Only God knows, but I am working day and night to realize it and things are moving at great and unexpected speed already (Dr X, 15 Feb 2002 ).
X's Problem
What is so problematic about setting up a hereditary disease register? Why does Dr X mention a nightmare? Concerns have been voiced about the effects of biobanking on society and vice versa. Th ese concerns cover issues of science, research policy-making, financial/economic, historical, and moral issues. But they do not form the drive behind Dr X's correspondence with politicians, anthropologists, and fellow scientists on biobanking. According to Dr X, his problems as head of the Division of Biotech and Research of Sanbe Farma, the main problem areas are:
• H uman resources : 'Here the concept of human resources refers to sampling targets. Prospects for genetic sampling in Indonesia look better than in the Netherlands.' • R esearch funding : 'Funding is needed for the purchase of expensive reagents. Funding from the Netherlands and relatively cheap scientific labour in Indonesia could utilise the economic and anthropological differences in the Netherlands and Indonesia.' • D ata collection : 'Needed are blood samples from ethnic groups, including each family's mDNA profile and a Y-chromosome set of DNA markers to verify their ethnicity. The question for Dr X is then how to map ethnicity in a quick and effective way.' • I nstitutional limitations : 'The academic bureaucracy and research regulation in the Netherlands set institutional limitations to scientific possibilities. At Sanbe Farma, Dr X enjoys relative freedom in setting up his research and receives respect from his colleagues and students.'
For Dr X to solve his problems, a scientific attitude, an entrepreneurial spirit, and the ambition to generate knowledge in the biomedical field seem to be essential on his path to scientific and human progress. After discussing his activities in the light of the paradigm of progress, a discussion of Dr X's biobanking activities will explore the possibility of regarding it in the context of 'exploitation' and as 'intellectual colonisation' and 'Orientalism'.
Progress

Scientific aspirations in genomics?
Dr X has various scientific aspirations and worries in the fields of genomics and biomedicine in general, and in the fields of DNA collection and molecular biology specifically.
Interested in the field of genomics, Dr X on 19 February 2002 proposed to people associated with the Dutch Genomics Initiative (NGI), such as its director Peter Folstar, Emil Broesterhuizen 5 and then-Minister Louk Hermans, to set up an Indonesian Satellite of the Dutch 'Genomics Institute', together with the Inter University Centre (IUC) Biotech of the Institut Teknologi Bandung (ITB, est. 1959 ) in Bandung (19 Feb 2002 . In Indonesia the ITB is highly rated in the field of medically oriented molecular biology. Dr X's own research group at Sanbe Farma had started an ambitious programme to type potentially new human papilloma viruses in Indonesia. Dr X regarded it as a prelude to an adequate vaccine against the development of cervical cancer, the major cancer problem in women in Indonesia At once, Dr X recommended organising a symposium entitled 'A Genomics Institute for Th e Netherlands and Indonesia'. Sanbe Farma and ITB would support local costs and run the organisation, and attract the best speakers from Indonesia, while the Dutch would send a delegation under the supervision of the new NWO Director, Peter Folstar. His serious intentions are expressed in his emphasis on the exchange of practical know-how so as 'not to "talk too much" but also "work a bit"'; 'Otherwise it easily becomes a waste of travel expenses and mere "scientific tourism" ' (19 Feb 2002) . Dr X's scientific endeavours were clearly linked to the aims of the so-called Human Genome Diversity Project (HGDP, discussed in section 3), as his challenge was 'to put Indonesian ethnicity onto the world DNA map' in general and to apply 'DNA mutational analyses of germ line mutations of the relevant genes for familial syndromes present in Indonesia' in particular. Some of these mutations, according to Dr X, may actually be specific for ethnic groups in Indonesia and in relation to ethnicity to be determined from mitochondrial DNA mutations 6 (19 Feb 2002) . Th us, Dr X proposed a programme for collecting DNA samples with genetic abnormalities of all of the over 200 [sic! ] 7 ethnic groups in Indonesia. Needing a map that gives him an indication of where to start collecting DNA samples, Dr X started to contact anthropologists. His main concerns here were the genetic deviations for familial cancer and mental retardation. All pedigrees were to be provided on the web with the request to the international community of genetics to assist with the detection of germ-line mutations.
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Close to his heart was finding a way to contribute to the development of science in Indonesia, for which he formulated new policies in the medical/ pharmaceutical field. On the basis of his experience of several years as a lecturer at Gadjah Mada, a very poor setting for science, followed by over a year in one of the richest settings, Dr X listed the basic principles he believes should govern a new Law, which he coined the 'Medical-Farmaceutical [sic] Research Law' (MFRL): 9 1. Medical doctors are surrogate 'tax' collectors from the poor in their private practices. If they are employed in universities/institutes of learning they tend to disregard science and progress in science as irrelevant and neglect their duties as 'scientists', so they must pay 'research tax' to make up for lack of duty (unless they can 'prove' by scientific papers and science citation index that they are fulfilling their scientific duties Apart from the central laboratory in Bandung, Dr X also has a laboratory in Jakarta (Dharmais) and Medan (USU). Additionally, he was building new ones in Semarang, Yogyakarta, Makassar, Surabaya and Bali/Lombok. Th e laboratories make DNA from collected blood, needed for scientific projects. It is possible, Dr X argued (21 Feb 2002) , to collect the blood on blotting paper in the jungle, dry it in the air, wrap it in a plastic envelope and send it off to a laboratory where the DNA can be purified. Dr X then recommended colleagues from the Netherlands (HJ) to come to Indonesia and 'claim' their department at the hospital and to start getting equipment together. Other experts, he invited to move into his microbiological and diagnostic labs. Always on the look-out for lucrative opportunities, Dr X was keen to approach key persons for funding: Th us, when Dr Henk Smits of the Royal Institute for Tropical Research (KIT, Amsterdam) 12 during his visit on 15 March offered his assistance, Dr X declared that he was prepared to 'take on anything that can generate medical progress in this country'. And on the occasion of Smits' official speech, he announced, 'we will have collected all established microbiologists and we will have invited a lot of them from other parts of 10 Similarly, to Peter Folstar, director of the NGI ('Dear Professor Folstar'), Dr X explained that despite the enormity of the job of the analysis of germ-line mutations, it can take place in Indonesia by using cheap labour and with careful planning. Th e main work could be done at ITB, while Sanbe Farma could make use of one of its MOUs to test all DNA containing adequate information on 'first right of refusal'. 13 To make Sanbe Farma more attractive, Dr X offered to look for other jobs related to molecular biology, varying from the genomes of mammals to those of bacteria. Apart from asking for advice about whom to contact in universities and departments of human genetics in the Netherlands, suggesting half-jokingly 'a little syndrome for each?' Dr X asked for a list of procedures for the analysis of rare syndromes and genetic deviation, which he could hunt for in Indonesia at the same time. And finally, an anthropologist was sent a copy of the correspondence. Th is anthropologist was meant to make an initial map of the tribes of Indonesia, to facilitate the search for genetic deviations in the 'jungle'. Adding to the given impression of a buzz of activity, Dr X poured out his satisfaction with his situation at Sanbe Farma:
My laboratory and the number of personnel are growing so fast that I can hardly keep up with it myself. God, now I realize how hard it has been to keep body and soul together in the Netherlands (but nevertheless [I had] 330 publications Gentlemen, so it could not have been me [!]) Four months later, in an e-letter to a critical colleague (CB), Dr X expressed his disappointment about the lack of support he has received: 'Over the last decades, the over 200 pharmaceutical companies (that have hardly any research and patents to speak of ) in Indonesia have meant nothing to science.' Th e newly available funding at PT Sanbe Farma for genetic research therefore causes amazement all around, especially considering the large amount of it, which he estimated to be over a million dollars and growing (Dr X, 24 June 2002, to CB).
An Enlightened Philanthropist in the Area of Health and Development?
Dr X has enlightened ideas about improving the world, especially where poor countries on the road to progress are concerned. He acknowledged that his plans for the registry 'may not be as pressing to the Indonesian government as are problems of infectious diseases, such as tuberculosis, malaria, dengue and emerging venereal diseases (ranging from HIV-induced syndromes to HPVinduced cervical cancer)'.
14 Dr X realised there was a need to attract research funding from elsewhere. Although the thalassemias have received attention from the Eijkman Institute for Molecular Biology, 15 and recently Fragile X syndrome and BRCA1/2 have also been looked into, he argued that other genetic disorders are understudied and diagnostic resources are sorely lacking. To remedy this situation, Dr X tried to attract attention from Broesterhuizen (NWO) to the importance of the education of researchers in Indonesia:
Continuous transfer of know-how through the young professionals is of course a must: 'A Progress in Methods is a Progress in Science is a Progress in Personal Development' should be the motto (Dr X, 19 Feb 2002) .
And when Dr X did not receive the desired support, realising that his plans did not fit the purpose of the Genomics funds, he was pleased that director Folstar at least was prepared to look for indirect channels of aid through education.
Dr X also stimulated researchers such as HJ and BT -'both of whom were born in Surabaya' -to visit his institute and: brainstorm about how to help Indonesia, beginning the reparation of ties between two peoples that after all have been connected for centuries, a feeling that is still alive and kicking ' (Dr X, 21 Feb 2002) . [transl. M-SF] Th ese forms of aid and 'people-bonding' were not confined to the historical relation and blood bonds between Indonesia and the Netherlands, but extended to possibilities for the people of Southeast Asia. With the promulgation of the Asian Free Trade Area (AFTA) in 2003, Dr X announced that:
14 Dr X' slideshow 'Th e Indonesian Hereditary Disease Registry' on http://www.ihdreg.com/ mainpage.htm (last visit: 8 February 2006) . 15 Th e Institute has established international reputations in such arenas as mitochondrial diseases and the study of hemoglobinopathies, and serves as Indonesia's national resource centre for genetic testing. http://www.eijkman-institute.org .
specialists from elsewhere can also come here to exercise their trade: borders will be opened and foreign competition for the Indonesian Medical People is on its way. About time, too (Dr X, 21 Feb 2002) . [transl. MS-F] Dr X expressed his belief that 'Perhaps this Program can be considered an "answer" from the poor world towards the Human Genomics Program -carried out by the affluent world'.
16 PT Sanbe Farma was willing to meet at least some of these costs for ethnic groups in the various parts of the country if it could take responsibility for the storage of DNA and the pedigree records to be displayed on the Web. 'Th is', Dr X emphasised, only in order to convince the Government eventually to take responsibility and create an Indonesian Human Genomics Program based on a modern resource of genetic material of humans and their diseases, a modern 'garden' like Bogor, with its huge resources of genetic material of plants from this island-rich vast Archipelago and its jungles, available for every serious scholar in this world (Dr X, 1 Aug 2002).
In short, providing scientific aid, building bridges, creating possibilities, and helping poorer nations in general were activities that Dr X, in his quest for support, held in high regard.
Exploitation?
Th e following sections make use of the insights of perspectives that critically observe genetic reductionism where others see scientific progress; they see imperialism in action where others see creative entrepreneurship and global free trade; and they spot Orientalist relations of inequality and intellectual colonisation where others see enlightened dedication and mutual help. Th ese critical perspectives in the first instance are used to view Dr X's activities in various theoretical light but in section four they are dismissed partly in favour of an institutional approach.
Reducing Humans and Peoples to their Genetic Make-Up?
As part of the Human Genome Diversity Project (HGDP), samples from indigenous populations, according to Luca Cavalli-Sforza, its initiator, human genetic data collections serve to avoid the irreversible loss of precious genetic information (1991) . Th e identification of genetic difference between ethnic groups (such as a different gene sequences that causes immunity to a disease) also is believed to have human (medical, cultural, and historical) and economic value. Th is perceived value has resulted in a new 'gold rush' where universities, governments, corporations, and private researchers are seeking to identify human genetic variation among remote populations (Marshall 1997) . Dr X clearly also recognises their value:
Southeast Asia with its more than 1000 ethnic groups, especially in the island-rich nations of Indonesia and the Philippines, many isolated since time immemorial and therefore unique founder gene mutations is in this respect one of the best genetic resources on Earth, probably superior to Africa, where mankind evolved and where genetic differences are the results of the longest evolutionary time, but where isolation of extended 'families' or 'ethnic groups' is clearly at a smaller scale (Dr X, Aug 2002).
Th e initial conceptualisation of the HGDP has been widely criticised for its consideration of indigenous peoples as mere research subjects, with little regard for their continued livelihood. Various ethnic groups have protested against population genetics, which they claim has been conducted without prior consultation and without consulting both individuals and the entire community involved (Knoppers 2003; Peterson 2001; Pilnick 2002; Sándor 2003; Sustrop 2004) . Because the HGDP was planning to collect blood samples some groups called the HGDP the 'Vampire project' (Lock 1994) , while others were angry because they believed that they were possible target populations even though no community representatives had been contacted about the project.
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While criticism of the HGDP was growing, plans for a so-called international haplotype map (the HapMap) were gaining support. Commercial and public efforts to assemble DNA polymorphisms were hoped to contribute to the discovery of single nucleotide polymorphisms (SNPs) that affect gene function. 18 Most successes in finding genes that contribute to disease risk have been for rare diseases caused by single genes, such as cystic fibrosis. 19 And it is these single-gene disorders that are the ones that Dr X proposes to register. But as shown by genetic research on individuals of Ashkenazi Jewish descent and African-Americans, concerns are raised about the augmentation of existing prejudices and genetic pretexts for discrimination in situations of conflict ing 17 For a long list of declarations against the HGDP, see Macer 1997: note 6. 18 Sites in the DNA sequence where individuals differ at a single DNA base are called single nucleotide polymorphisms (SNPs). A haplotype is a pattern of SNPs on a block of inherited sets of nearby SNPs on the same chromosome.
19 To locate such genes researchers perform linkage analysis on families, which requires 300-500 highly informative genetic markers spanning the entire human genome. political and socio-economic interests.
20 Considering its history of ethnic strife and discrimination of the mentally handicapped, Indonesia may be no exception.
Other questions concern the ways in which genetic/ethnic populations are defined in the first place. Population geneticists hope that identifying differences in genetic sequences between peoples will help determine what makes groups of people different from others. Dr X believed that anthropologists can help him by drawing ethnographic maps for him to use as a compass for the selection of ethnic groups so as to make a DNA map. Asking an anthropologist, FH, to lecture on 'Th e Ethnic Groups of Indonesia: traditional and molecular anthropology' seemed to indicate a naivety about the political and cultural history of Indonesia. Moreover, the question in itself presumed that biological and cultural histories are rather static and apolitical. Explaining his frustration in getting Prof Sangkot Marzuki, a molecular geneticist involved in mDNA research, to provide him with the 'manuscript' of his work that could serve as a blueprint or ethnic map, Dr X concludes:
Perhaps it is published already and it is likely that I now need to have the mDNA profile of every family and possibly even a Y-chromosome set of DNA markers to verify ethnicity. But before I have set it up, naturally, I can deduce from the name etc. etc. which group I'm dealing with.
21 [Transl. MS-F] Of course, other factors also contribute to population differences, such as culture, language, environment, and experience. If these factors are neglected in the definition of populations, one may ask if haplotyping would give privilege to some group definitions over others. What would be the effect of the creation of new socio-genetic boundaries between populations?
Does Dr X's Data Collection Constitute Imperialist Exploitation?
Concerns exist about who will have access to the collected data, which socioeconomic groups will be able to turn these data into profit, and which genetic diseases will be the focus of research. It was mainly such concerns that led Asian nations to set up their own Haplotyping initiative.
22 20 It should be pointed out here that race is a social category presumed to refer to 'nature' (Cf. Wade 2003) . 21 Two years later, going by the registry published on the web, there is still no evidence that ethnic labels on the DNA of samples collected from his families are in use (cf. http://www. ihdreg.com/mainpage.htm last visit: 8 February 2006). 22 In November 2004, the HUGO Pacific Pan-Asian SNP Initiative was established by scientists from China, India, Indonesia, Japan, Koreas, Malaysia, Nepal, Philippines, Singapore, Th ailand, Although Dr X made much of his intention to share information by placing collected data on the internet, this gesture was not as generous as it seems. On the registry website Dr X announced:
Our Registry is in the beginning and we plan to present all relevant family information on the Web. Requests for help in gene mutation searches will be given only if the pedigree is as complete as possible, if relevant medical records are sufficient, if enough DNA is present to send out aliquots to interested groups worldwide and if we are not doing the analysis ourselves (Dr X, 1 Aug 2002).
In other words, considerable work has already been done on the pedigrees. Moreover, medical records needed to be sufficient, which brought into question the protection of privacy of patients. Further on in the article, it becomes clear that providing information on founder genes on the Web is merely a cheap way of getting others to help.
Once published, specific data on the kind of mutations, whether it is a founder gene mutation of a certain ethnic group etc. will also be revealed on our Web site and sub- Here Dr X seems to be simply playing on Dutch anxieties about missing out on good opportunities to access valuable human research materials, and consequently research publications, fame and funding. Who knows, patents could be developed and Sanbe Farma could play a crucial role in a project that might ultimately be supported by the central government of Indonesia.
and Taiwan, aiming to look at 50,000 SNPs in each study participant (see the homepage of the Genome Institute of Singapore, available at: www.gis.a-star.edu.sg/homepage/gismediapress. jsp?pid=33).
Despite big plans for building laboratories and gaining access to the DNA samples of families from hundreds of ethnic groups, the issue of sample shortage reigned:
For as yet I do not even have 10 families here in Bandung (I heard from Gerard that you have 23 from Yogyakarta) and I am a little ashamed about my big mouth, but I can assure you that the entire process of looking for families has begun and is progressing faster and faster. Before the end of the year I will certainly have over a 100 families and the number will accelerate exponentially when the satellite laboratories are running properly (until now only a few families from Medan), but in Semarang (Dr Sultana Hussein, a genetics star in the Indonesian firmament, with which we cooperate closely and have given much money to) there is an entire school (Semin) with Fragile-X syndrome, 23 as you know Ben (Dr X, 23 Feb 2002) . [Transl. MS-F] Th e bottom line seems to be money, after all:
Ah, before I forget: we can employ 20 biologists here for the same price of one over there with you. And I can assure you that they are at least as smart. And once they get the chance to work they gain experience fast enough, and we work here until Saturday afternoon (Dr X, 23 Feb 2002) .
[transl. MS-F]
Does Dr X's Attitude Express Orientalism and his Work Intellectual Colonisation?
According to Edward Said, Orientalism is a 'Western style for dominating, restructuring, and having authority over the Orient'. Th at authority was the ability to say what was and was not 'Oriental'. Th is usually includes:
a. An inversion of what is thought to be European civilisation, justifying attempts to enlighten of the backward Other); b. Taking over values of the Oriental elite, gaining a foothold in the Orient by supporting the local elites; c. An inversion of history that recognises the Orient as a richness of historical resources) (Cf. Said 1979: 1-9).
As a generic term, Orientalism refers to distortions in the perception and analysis of Other cultures. One distortion is exaggerating the difference between the familiar and the strange: a focus on the exotic. Another distortion is treating a society as though it is an unchanging expression of some basic essence or genius (essentialism). Here, social and cultural practices and institutions are portrayed as being 'what they are because they are what they are' ontologically (so that no empirical material can alter or dislodge the claims made). A third distortion portrays and analyses Oriental society as though it is radically separated from the West. Th is occurs especially in works that ignore points of painful contact between this Other society and the West, ignoring the adverse effects of colonial relations and ignoring Western intrusions in that society. Perhaps even more aptly, could Dr X's project be viewed in terms of 'intellectual colonisation', a term coined by Abdur Rahman, and denoting the belittlement of indigenous knowledge in favour of the establishment of Western science institutions, while ignoring the basic human needs of the masses. Th is bias would keep Th ird World state underdeveloped through a deliberate policy of indoctrinating indigenous elites with Western scientific concepts (Cf Rahman 1983) . Th us, in Dr X's plans to set up a joint registry, Indonesians and their DNA were the objects of research, but no Indonesian voices were heard. Is this a coincidence? Quoted reasons for setting up the registry included stimulating local research, providing medicine, placing Indonesia genetically on a world map, and this was all done in cooperation with a large pharmaceutical company, Sanbe Farma. Not only did the registry support the educated elite of Indonesia, Dr X's enlightened charity to the poor in the 'jungle' and his attempt to place their DNA on the World Human Genome Map could be viewed as paternalistic. Furthermore, just a few years of experience seems to be sufficient to Dr X to formulate Indonesian science policies:
In the mean time I am now able to 'formulate' a new Science Policy for this Country in the Medical/Pharmaceutical fields after having worked for several years as Lecturer at Gadjah Mada in a very poor setting for science, followed by over a year now in one of the richest settings for science in this country.
Prompting colleagues to come to Indonesia seems to play on a sense of paternal benevolence:
Compared to the Netherlands 'nothing is finished' here and over there 'everything is finished'. You are no longer really needed over there, H, but here you are really needed (to HJ). [transl. MS-F] Th is benevolence seems to be naturally 'Dutch': An 'ex-pat' from 'Belanda' is still in people's good books, especially with the elderly who immediately start speaking Dutch and are proud they still can. And of course they still need all the help in the world necessary to keep/make this gigantic archipelago inhabitable for hundreds of million people (21 Feb 2002, to HJ) . [transl. MS-F] Speaking of recreating a bond between the educated elites of the Netherlands and its former colony, Indonesia, Dr X seems blissfully innocent of the atrocities associated with that same history (Multatuli 1969 (Multatuli [1875 ):
I take the liberty of sending this message to the people involved as well as to Minister Hermans whom -or so I wish to think -would not be adverse to such a 'joint venture', re-establishing the links between the respective communities of high learning of two countries which -alas [sic! ] -had such strong bonds in the past and I am sure strong dreams for a combined future (19 Feb 2002, to EB). His efforts seemed to be those of a misunderstood fighter for a great cause:
Th anks again for your message, which I need once in a while to 'air' my thoughts and to 'keep my job'. Even a Don Quichotte needs recognition, I believe, if only from Sancho Pancha, and especially when he is chasing windmills far away from home. Don after all was 'at home' in Spain, was he not (21 Feb 2002, 
to HJ). [transl. MS-F]
To his critical colleague CB he expressed amazement when CB points out some of the political dangers of his project: Did Dr X really not know about the politics and bioethical complications of genetic sampling and setting up databases?
An Institutional Approach
An institutional approach to the cluster of problems/solutions associated with Dr X's proposal for a genetic family registry can help us understand why and how an adequate institutional embedding is crucial to the development and application of new technologies. In other words, a study of the functional connections between institutional developments and the problems/solutions put forward by the paradigms of Exploitation and Progress has the potential of PROGRESS Individuals are important to work with or to mobilise, but as object of research they become part of a common human genome. At the same time, genetic group differences generate new knowledge and medicine.
EXPLOITATION Individuals are socio-economic beings, some of whom are victims of the capitalist system, which alters them qualitatively into objects of research (including genomics) and capital flows.
PROGRESS
Academic and organisational structures are invisible, apart from when they are in the way; then they are noticed as bureaucratic obstacles or as political instruments.
EXPLOITATION
Market mechanisms under capitalism and historical relations of socio-economic dependency have set the political stakes against poor, non-Western countries.
PROGRESS
The global is the local when taking into account the cost of the movement of scarce resources such as capital, skills, and sources of production. All one needs is good planning, know-how, and people who want to cooperate.
EXPLOITATION
Globalisation means a capitalist ('Western') penetration of the local community, homogenising human diversity at the expense of local traditions. PROGRESS Indonesia's past colonial ties with the Netherlands and the exploration of future diseases are meaningful as assets. They are the main points of departure in the proposals for the registry and a Dutch-Indonesia Genomics Project. EXPLOITATION Indonesia's present underdevelopment is directly related to her past colonial subordination, while her future seems to be dependent on lingering corrupt political systems determining the country's fate through her economic and political links with globalising imperialist structures. An institutional understanding recognises that social, technical, and economic institutions are interdependent, which necessitates a critical analysis of relations between society and individual, the infrastructure of social, political, and legal institutions, the way local communities adapt to globalizing trends, and pronouncements referring to collective memories and aspiration. Th e six views discussed, however, tend to verge towards either the paradigm that I call Progress, or the paradigm that I call Exploitation.
Th ese stereotypical views can inhibit attempts to understand actual processes of change that involve altering relations between the individual and the group, the local and the global, and changing views of time. A closer look at biobanking in the context of malfunctioning institutions shall make clear that the validity of the six perspectives discussed above depends largely on the particular constellation of institutional settings important to the development of biobanks.
In the absence of adequate healthcare, educational, and other institutions, individuals can hardly be expected to give their informed consent freely to cooperate in projects that may have consequences for their mental and physical health and their political and ethnic identity. One of the main issues in bioethics concerns the question as to whether and in what situations research on human subjects is justifiable. Considerations, discussed here, range from large politico-economic issues of national policy-making and trust in government institutions to the supervisory capacity of bureaucracy and public spending on healthcare and sanitation.
Disjointed Institutional Embedding
Although Indonesia in the first part of the 1990s as one of the eight Asian tigers had annual growth percentages of 6-8%, the unexpected 'Asian crisis' in 1997-98 turned these into decline. Economic development had a negative effect on the development of Indonesian bioethics in a very basic sense: food prices shot up, and the poor -by 1998 about 60% of the population lived below the poverty line -were hurt. Recovery in Indonesia was comparatively slow, as it was complicated by problems accompanying the shift of power at the end of thirty-two years of authoritarian rule under President Sukarno. Although the following 'reformasi' was gradual and patchy, in 2002 the percentage of people living below the poverty line had decreased to 27%. 25 25 ADB (Asian Development Outlook) GDP of Indonesia: 1997: 3,2; 1998: −14,7; 1999: −0,7; 2000: 3,3; 2001: 1,9; : 2.2 (Bergstrom 2004 .
Nevertheless, the GDP in 2002 averaged at just US$994 per capita, the unemployment rate was 9.1%, 23 and the situation in the areas of sanitation, healthcare, and nutrition was poor. Moreover, according to UNDP Human Development Report 2001, 24 66% of the population was not using adequate sanitation and 24% of the population was not using improved water resources. Th e proportion of underweight children under five (1995) (1996) (1997) (1998) (1999) (2000) was 34%, undernourished children 6%, and under-height children 42%. 26 It should be clear that Indonesia was not just waiting for high-tech solutions to its healthcare problems.
Nirmal Kumar Ganguly, Director General, Indian Council of Medical Research (ICMR), emphasised the broad healthcare needs:
Against the background of the attainment by all of health rights, achievement of global health equity, increase in healthy life expectancy, and access for all to essential, quality health services the evolution of bioethics needs to be traced to its present concern with the health of populations, and identify some of the most important inequalities that confront contemporary society.
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A particular sensitive issue Ganguly defined as follows:
Potential conflict exists between policies aimed at reaching vulnerable groups and those seeking to achieve aggregate health benefits (see footnote 24).
Th e concept of vulnerable groups here refers to those who cannot afford or do not have access to basic healthcare facilities. Th ese are the circumstances one has to think of when 'ethnic families in the jungle' are asked to provide blood samples for a registry on the web. 28 When institutions essential to daily survival, such as healthcare institutions, social and economic security (through local institutions such as the family or local associations or government institutions) and legal institutions that regulate and overview research and healthcare are not securely embedded in society, vulnerable people may be in no position to make a free and informed decision about participation in a project on their 'deviant' genetic make-up. Th e risk of genetic stigma, and the unavailability of financial means to purchase medicine, receive genetic counselling or 28 Also take into account that the adult illiteracy rate is 13.7% and that only 13 per 1000 Indonesians own a PC in 1999 (WDP Report 1999 /2000 , Bergstrom 2004 genetic therapy, means that, besides the high risk of physical suffering, they and their families carry a great burden of psychological and material uncertainty. As the development of welfare institutions may take decades, this problem should be viewed as structural.
Nevertheless, without fully realising the consequences of research on their genetic make-up, it is tempting for families to join a project against little in return. Th e cruel attraction of Indonesian people as rich biological resource, therefore, lies not only in the unique and valuable nature of their DNA, but also in the relative ease with which in the foreseeable future research permits are received, bureaucratic procedures can be avoided, the low price of schooled labour, and the relative lack of resistance that vulnerable (illiterate, uneducated, or poor) people display to becoming targets of research. As has become clear from the history of bioethics in Indonesia, the institutional embedding is missing.
It was only in the late 1980s that the Indonesian Medical Association formulated ethical guidelines for medical research, but they spread slowly and were mainly based on a 'Western' model. In 1995, government regulation concerning health research and development were put in place. Of special relevance is Chapter IV on health research on human beings, prescribing informed consent, health and safety measures, provision of information on the research in question, and the protection of confidentiality of patient information and records. 29 However, the institutional capacity to enforce compliance to these guidelines is weak. Apart from lacking resources to do so on the part of the government, it has also proven difficult to integrate medical ethics with the extant medical curriculum in universities (Sjamsuhidajat 2004: 51-2) .
Not until after issuing the 'Guidelines for Good Clinical Practice' by the Indonesian FDA and the translation of 'WHO Operational Guidelines for the Operation for Ethics Committees' in 2001 that the Ministry of Health (MOH) in October 2002 established a National Committee on the Ethics of Health Research (NCEHR). 30 According to a joint study by the Indonesian Ministry of Health and the WHO, twenty-six sub-national ethical review committees were set up in eleven provinces. However, the study also shows that there was no single standard among these various committees with regard to membership or procedure, as well as the perception of bioethics in health research. It led to doubts about its effectiveness. 31 Th e capacity to oversee clinical research and compliance with guidelines are especially in need of reinforcement (Slamet & Mark 2002: 77) .
Th e inefficacy of research guidelines is partly related to a poor functioning bureaucracy. Systemic corruption and a lack of legal certainty can also partly explain the uncompetitive environment for conducting business and slow economic recovery from the financial crisis in the late 1990s. Additionally, economic problems are due to recent acts of terrorism, unequal resource distribution among regions, a lack of reliable legal institutions, a weak banking system, and endemic corruption. While traditional sources for financial and legal aid, health, and social security have weakened during the period of industrial and urban expansion in the 1980s and 1990s, governmental and non-governmental institutions have not been able to fill this gap (Abdullah & Hüsken 2003) .
Bureaucratic institutions in general tend to protect their own interests (Douglas 1986 ), produce indifference (Herzfield 1992) , and recognise the existence of (other) individuals only by their own (legal/administrative) criteria and in their own time (planning) (Bendix 1962) . And when corruption becomes endemic, informal ties and personal interests may feed on formal tasks, rendering the implementation of any new reform programme slow and contradictory. Th e general inability of the government to deal with what is commonly called KKN (the Indonesian acronym for corruption, collusion, and nepotism) as well as a failing justice system has turned Indonesia into an enigma. 32 Comparing the institutional confusion, which has come about after the ousting of President Suharto, to a show of wayang kulit (shadow puppetry), it is no longer clear who plays the role of the puppet-master. Th e well-lubricated government bureaucracy remains unable to stem diversion of state-owned funds into individual pockets before reaching their intended destination, including healthcare institutions. In short, without welfare institutions, effective supervisory organs, and a financially secure population, families and individuals do not have the required support to decide about entrusting their DNA samples to biobanking projects.
Institutional Mobilisation and Dr X's Initiative
In February 2002, Sanbe Farma was flourishing. As, on a global level, governments were pouring funding into genomics, the Progress paradigm flourished too. Official institutional exchanges between Indonesia and the Netherlands in the areas of biotechnology started growing in 1992, nearly 10 years before Dr X would start to lead the department of biotechnology and research at Sanbe Farma. Th e visit of representatives of the KNAW and project leaders to Bandung in February 2002, 33 led by Minister Hermans, was closely linked to the activities of the Eijkman Institute for Molecular Biology. Sangkot Marzuki, who had led the institute since its re-opening in 1992, was a strong competitor for biotech funding in the areas of molecular diagnostics and genetic sampling. Th e institute's success in obtaining funding and support raised Dr X's envy:
We have hardly anything in Indonesia, apart from the Eijkman but I'd rather not involve him if it is not necessary, for they are 'competition' in Jakarta (Sangkot Marzuki), who in this respect receives everything from the Government and all others receive zilch, and if elsewhere they receive something they make a mess of it). He [Marzuki] focuses on the hemoglobinopathies (Dr X, 23 Feb 2002) . [Transl. MS-F] It was during the 1992 trip that Minister Hermans had asked Dr X's opinion about activities in Indonesia and it was at that occasion that Broesterhuizen had told Dr X about plans for a genomics programme, which Dr X took to be a possibility for future cooperation (Dr X, 24 June 2002). Furthermore, it was when Dr X was working on a Konigin Wilhelmina Fonds (KWF, a Dutch cancer charity) project in Yogjakarta, that he was asked to come and set up research at Sanbe Farma. When Dr X spoke with Minister Hermans, he had already set up a laboratory and had employed some academics of ITB, so that it was only natural for Dr X to see fertile grounds for cooperation. In fact, it is the entire institutional set up of KNAW and KWF that led to opportunities for them to have the meeting in the first place.
At the same time, Dr X took every opportunity to mobilise his and other people's institutional networks, ranging from Indonesia and Singapore to the Netherlands. In his e-letter to HJ, Dr X relates how he had managed to befriend the Rektor of ITB, Kusmayanto, musing that 'according to tradition will become the next Minister of Research & Technology', and proposed to start preparations for his new 'Medical Pharmaceutical Research Law' (21 Feb 2002) . It is of great importance for Dr X not just to be treated with respect, but also to be accepted in the company's institutional culture:
33 Two MOUs were signed by the Dutch and Indonesian ministers in support of the Scientific Programme Indonesia-Netherlands (SPIN) coordinated by Th e Royal Netherlands Academy of Arts and Sciences (KNAW). Since 1997, infectious diseases and biotechnology constitute two of the six focus points of research (Stapel 2003) .
At work they have started to call me Pak Jo now, instead of Dr Jo, after the example of the Rector [Kusmayanto of ITB]. In short, I am accepted as one of them and no longer the odd man out. My young academics and other personnel worship me and it is a pleasure to work day and night (22 Feb 2002, to HJ) . [transl. MS-F] Dr X feels clearly more 'at home' at Sanbe Farma than at his former laboratory at the Free University (VU, Amsterdam):
And in fact I can do top research again without any further restrictions, and as well as in my laboratory at the VU: I no longer can see the difference between my laboratory here (over 10 permanent staff work there already) [which] has nearly doubled in size of what I had at the VU and with which I ended [my stay]. Last week, again, I acquired a full-time molecular biologists (yes, promoted and all and top of the nation here) and a full-time pathologist. And one day soon we will purchase a Cytovision caryology system of US$100,000, while we are selecting the Flow Cytometer at the moment. You would not think it possible in Indonesia, would you? (22 Feb 2002, to HJ) .
[transl. MS-F] When in March 2001, the Genome Institute of Singapore (GIS) was set up as the national flagship program for the genomic sciences in Singapore, Dr X had seen an opportunity for sampling activities to transgress Indonesian borders:
In Singapore a 'Genomic Institute' has just been set up by a Prof. Dr. Ed Liu, 34 who is pleased to co-ordinate things with me and with whom I want to observe all of the 500+ Southeast Asian ethnic groups by looking for support in the Philippines, Malaysia, Th ailand and the rest of the 'region'. Of course this is something else, something that even entire Europe cannot beat for all of these 'ethnic' groups are just 'large families' of course, who have lived in isolation in this gigantic archipelago for thousands and thousands of years (23 Feb 2002, to P en G (VU) , B en F (KUN), D (EUR)(via HJ), C (RUG) en G (Ingeny in Goes). [transl. MS-F] Judging from the 2004 Hapmap initiative to haplotype Asian DNA, however, it seems that Marzuki's prestigious institute had already filled in the slot for Indonesia (Normile 2004) .
Chances of Dutch governmental support seemed more promising. Despite his widespread cynicism about the uprightness of Dutch political institutions, Dr X's faith in them is strong enough for him to believe that a reasonable proposal will be considered for its scientific merits. For this reason, Dr X expressed the hope that the Minister for Education, Louk Hermans, would 34 Dr Edison Liu, Executive Director of the Genomics Institute of Singapore (GIS).
'play Father Christmas'. After all, Hermans had 'just given 2 million Euros to the charity for sports and children run by 'Kus' (Kusmayanto, the Rector of ITB), surely leaving enough to spend some more -e.g., US$80 million before stepping down. ' (22 Feb 2002, to HJ) Th rough the Minister and the vice-director of the Board of Education and Science, Emil Broesterhuizen, he was introduced to NGI director Peter Folstar, who showed interest in the idea of a joint Indonesian-Dutch genomics institute (Dr X, 23 Feb 2002) . Although happy to have direct access to the 'highest Dutch genome', it did not diminish Dr X's distaste for following due 'bureaucratic procedures' necessary to gain access to funding:
In the Netherlands I have developed an extreme distaste for writing down plans for nothing, even though my score at the KWF was over 80% over 30 years of cancer research. So I have written a concise plan to Mr Broesterhuizen and I shall add a first draft of our planned home page to be called 'Th e Indonesian Hereditary Disease Registry ' (22 Feb 2002, to PF) . [transl. MS-F] Having been successful and having valuable resources on offer, Dr X preferred to disregard due procedures:
Now I do hope that you won't be sending me a pile of forms, for then I will get up on my hind legs. I am so happy to have been able to avoid them here in Indonesia over the last three years. Th e precise contents of the plans will come later, me thinks (sic!), and I shall welcome any suggestion from the Netherlands. We are prepared to take on anything as long as we can establish a beginning of cooperation. Th ere are hundreds here rearing to go but can't find a job and if they do they have no money to conduct experiments. A sad situation here, apart from with me at Sanbe Farma fortunately. (22 Feb 2002, to PF) . [transl. MS-F] Dr X seemed to know how to pull the strings in the Indonesian bureaucracy and understands how to approach the right person in the right institutions:
Furthermore, we are setting up one or more 'field' teams that carry out expeditions, such as to Papua and the inlands of Sulawesi, Kalimantan and Sumatra. To approach small ethnic groups permits are required from a specially designated Ministry. All contact with the Government from here: NOT OTHER WAY ROUND PLEASE. So Louk, Emil and others, please, do not play the big guy in Jakarta. It is better if we, i.e., Pak Jahja, my boss at Sanbe 35 and 'Kus', the Rector of ITB, present ourselves as 'small boys' with an offer from the Netherlands. We know the 'right price' to pay (you 35 Dr Jahja Santoso, Apt., President Director of Sanbe Farma.
don't, which would end in a right disaster) named KKN [corruption, collusion and nepotism] 36 (try to translate that in proper Dutch) (23 Feb 2002) . [transl. MS-F] Th e special nature of the Indonesian bureaucracy apparently requires special treatment. But when about four months later official enthusiasm subsided, Dr X started to question continuing the discussion with geneticist in universities (24 June 2002, to CB). When 'asked what he really wanted'(24 June 2002, to CB), Dr X set his aims less high, stating that he did not really want to do much more than what is common practice in the Netherlands already: collecting materials from families with genetic deviations to perform routine molecular diagnostics. Surmising that the new Dutch infrastructure was 'rather enormous', Dr X also considered trying to find susceptibility genes indicative of complex genetic diseases. But it was not really his field -making a contribution to the Human Genetic Diversity Project had been his main scientific dream (24 June 2002, to CB).
It was Dr X's institutional position that enabled him to mobilise contacts from Southeast Asia, apply for funding in the Netherlands, using his contacts in Dutch universities and government organs, employ cheap highly educated labour in Indonesia, and pull strings in the Indonesian bureaucracy. His privileged position can be understood as generated, partly, thanks to the institutional structures and relations of inequality prevailing under oppressive regimes in the Dutch colonial and republican postcolonial eras.
Malleable and Disjointed Institutions
It was not only the Dutch-Indonesian colonial history, but also global developments in biotechnology that have produced the institutional conditions for an entrepreneur-cum-scientist (-cum poet) to mobilise potentially fruitful partnerships in biobanking. Vis-à-vis his colleagues, Dr X put up a show of feeling at home and being respected far away from home in Indonesia, while making sure to communicate the impression that he could move mountains at will. Both showing off how he rubbed shoulders with the world's greatest and giving the impression that he (and the other greats) could take on the challenge of finding the key to Asian genetic diversity were not only an expression 36 Most Indonesians are agreed that political 'reformasi' since 1998 and the fall of Suharto have failed to check corruption, commonly referred to as KKN. Th e government of President Susilo Bambang Yudhoyono has made the fight against KKN its chief priority, but the results so far have been disappointing. of his vanity, but, more importantly, conditioned by the institutions that he was in a position to mobilise.
Vis-à-vis official organisations, he could not take the same stance -showing at least some respect for the rules he believed necessary to get past them. As in any bureaucracy, there are ways of manipulating bureaucratic administration, such as by searching alternative readings of the rules or by simply playing on the sensitivities of a functionary. Th e bureaucrat, in turn, can learn how to deal with troublesome cases and may take steps in order to improve procedures. In the case of Dr X, his unwillingness to follow official procedures in the Netherlands was accompanied by pulling strings among his contacts in the Netherlands. In the end it did not yield any funding, which was largely reserved for the Genome Initiative in the Netherlands. A healthy or successful bureaucracy, therefore, is relatively dynamic. It may be slow and in need of correction from time to time, but it is transparent enough for the procedures to correspond roughly to their functions.
A 'corrupt' bureaucracy, however, has no effective standard procedures. Individuals in the bureaucracy have control over resources that they use to build up internal and external relations of reciprocity. Th e price of 'their' resources is variable, depending on the relation with and the resources of the clientele. In dealing with such a bureaucracy the client needs tact and humility. Dutch big shots insisting on their rights could endanger existing deals between the authorities and Sanbe Farma.
Essential to Dr X's plan to create a registry and to map Indonesian DNA, a range of institutional settings were involved:
• funding institutions (private, public, government) • educational institutions • healthcare institutions • institutions that design research regulations It is clear that in the Netherlands there was more funding available than in Indonesia (despite Dr X's positive experience at Sanbe Farma). High-quality researchers in Indonesia were cheaper than they were in the Netherlands, and were highly motivated and disciplined. In Indonesia, healthcare institutions could hardly cover the needs of the population, but they were mobilised in getting the poor to cooperate in projects that might have no positive consequences for them. Now that we have involved the Puskesmas [community health centres] (68 in total) of Bandung, things are really starting to get cracking and the aim is to involve the local healthcare organisation of the entire country in an enormous national programme, for which there are more then enough means available (21 Feb 2002, to FH) . [transl. MS-F] Such determined optimism leads one to believe that Dr X either had no clue about the existence of research regulation or that he was banking on paying him an agreeable price.
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It should be noted that the NCEHR and the INBC were set up after Dr X's e-discussion on the Indonesian Dutch Genome initiative took place. Th at may be why not a word has been dedicated to informed consent procedures, the explanation of the research procedures, or its medical and financial purposes to laypeople. No consideration was given to the political consequences for the individuals involved, their families, and the ethnic communities. But how will patient confidentiality with regard to the identity and health records be maintained if according to government regulations 'Requests for help in gene mutation searches will be given only if the pedigree is as complete as possible, if relevant medical records are sufficient?' 38 No effort is made to elaborate on how those who are found genetically deviant for, for instance, familial cancer and mental retardation shall have to deal with their condition, and what precautions and what measures should be taken. Th ese questions are the more urgent, considering that historically in Indonesian society there has been a tendency to regard patients with mental illness as a threat to those around them rather than sick people in need of support and care. Th e fifth ethical principle of the World Medical Association on Ethical Issues Concerning Patients with Mental Illness, adopted by the 47th General Assembly in Bali in September 1995, states: 'Th e confidentiality and privacy of all patients should be safeguarded. When required by law, the psychiatrist should disclose only the relevant material and only to the relevant authority. Data banks which allow automatic transfer of information from one authority to another may be used provided that medical confidentiality is respected.' 39 After diagnosis, 37 Th e Government Regulation of the Republic of Indonesia No. 39 of 1995 concerning health research and development was established on 14 November 1995. According to Chapter IV, Article 8, health research and development involving human beings may only be carried out with the written consent of the person concerned or, where appropriate, his parents or heirs. Under Article 9, such research and development is to be carried out with due regard for the health and safety of the person concerned, his family, or the community; Article 10 prescribes that the person concerned, his family, and the community have the right to obtain information on the purpose of the study, the methods used, and any risks entailed prior to the commencement of the activities concerned; Article 11 requires the research and development organiser to maintain confidentiality with regard to the identity and health records of the persons concerned; Article 13 places restrictions on the extent to which children, pregnant or nursing women, and mentally disabled persons may participate in research and development; and Article 15 states that the results of health research and development may only be applied if justified from the standpoint of human health and safety. 38 problems exist not only in the areas of access to medical treatment and therapy but also in the areas of ethical decision-making and law. But what if prenatal diagnosis reveals a high risk of familial cancer or mental retardation in a country that has declared abortion illegal, even when the mother is in mental or physical danger, carries a defective child, or has no means to look after the newborn baby? 40
Conclusion
In this article I have made a distinction between the biobanker as a scientist, an entrepreneur, and an enlightened thinker. Dr X as a scientist had wanted to explore the human genome and set up a registry for Indonesian families of various ethnic backgrounds with deviant genetic make-ups, mainly directed at familial cancers and mental retardation. Dr X, the enlightened, would have wanted to facilitate molecular diagnostics and the generation of knowledge on monogenetic diseases, while it required Dr X the entrepreneur to mobilise sufficient resources.
I have also made a distinction between the paradigm of Progress and the paradigm of Exploitation. Neither paradigm seems to be adequate without an approach that takes into consideration the political economy of a country and its welfare, educational, and regulatory institutions. Without coming to any conclusions about Dr X's motives for 'collecting families' in Indonesia, his plan was based partly on his access to the DNA of vulnerable people, the availability of historical and institutional ties between the Netherlands and Indonesia, the relative difference in the prices of educated labour, his access to funding, and disjointed welfare and legal institutions in a country that recently has experienced great political turmoil and economic calamity.
Indonesian welfare institutions do not provide the required protection for economically and politically vulnerable individuals for them to effectively exercise free informed consent to cooperating in genetic research on familial cancers and mental retardation. Considering the fast modernisation and industrialisation of Indonesia in the 1980s and the first half of the 1990s, the group ties of traditional communities have become looser and have been replaced, partly, by new ones. Group consent for participation, therefore, may not be an option either. Responsible practices of informed consent procedures would require the establishment of effective institutions enabling individuals and groups to exercise the choices that people have in wealthier societies.
Like modernity, modern science is more than just a set of institutions or structures. It is embedded in economic as well as cultural environments. If the enhancement of scientific capacity in Indonesia is to contribute to economic progress and strengthen the position of Indonesia in the world, in the long run, it shall have to be based on institutions that articulate the country's needs with the socio-cultural and politico-economic situation of those whose cooperation they seek: vulnerable communities and tribes with inadequate means of subsistence. Experience in the 1990s in the People's Republic of China has shown that without proper regulation for informed consent, people in isolated communities get hurt and resisted, while suspicion of scientific experiments easily spreads (Sleeboom 2005) . Scientific entrepreneurs will have to deal with the local problems generated by the adaptation of scientific experiment and help to create the appropriate legal and healthcare institutions for them to build upon. Indeed, Dr X may be doing so now.
